Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.

Mark L WarrenBruce BodeJang I ChoRong LiuJanet TobianThomas HardyFarai ChigutsaMoshe PhillipBarry HorowitzDebra Ignaut

Published in: Diabetes, obesity & metabolism (2021)

URLi was efficacious, providing superior PPG control and less time in hypoglycaemia but with more frequent infusion-site reactions compared with lispro when administered by CSII.

Keyphrases

type diabetes
glycemic control
blood glucose
low dose
cardiovascular disease
insulin resistance
high resolution
blood pressure
skeletal muscle